Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track FMS with free AI briefings, catalyst countdowns, and dilution alerts.

FMS · Fresenius Medical Care AG

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1.1B Cash on Hand
CF+ Cash Runway
Follow FMS by email Get an email when FMS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about FMS, unsubscribe in one click. Privacy

📣 What FMS Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Fish Oil
FDA approved Jul 2018 · Omegaven
Critical Illness Phase 2 · NCT07883447 Recruiting
Smoflipid Malnutrition, Child Phase 4 · NCT06049680 Recruiting
FKS518 Postmenopausal Osteoporosis Phase 3 · NCT04934072 Completed
Patiromer Powder for Oral Suspension (Part A) Hyperkalemia Phase 3 · NCT05136664 Completed
Patiromer Powder for Orals Suspension (Part B) Hyperkalemia Phase 3 · NCT05136664 Completed
Fresubin Supportan Head &Amp;Amp; Neck Squamous Cell Carcinoma Phase 1/2 · NCT07180576 Not yet recruiting
Omegaven® (fish oil triglycerides) Injectable… Parenteral Nutrition Associated Liver Disease (PNALD) N/A · NCT06274788 Recruiting

Also used in these trials (approved or third-party drugs, not FMS's own candidates): Difelikefalin, Denosumab, Tocilizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

FMS holds $1.1B in cash and short-term investments and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when FMS files for a raise →

👥 Who Owns FMS

Insiders 0% Other 5%+ holders 32.4% Institutions (272 holders) 10.1% Public and other holders 57.5%
HolderTypeShares% of sharesAs of
Fresenius SE & Co. KGaA 5%+ holder (13D) 53,738,118 19.24% 2026-11-11
Fresenius Medical Care Holdings, Inc. 5%+ holder (13D) 18,312,735 6.56% 2026-01-01
Fresenius Medical Care AG 5%+ holder (13D) 18,312,735 6.56% 2025-10-08
BlackRock, Inc. Institution (13G, 5%+) 13,447,914 4.82% 2026-06-30

Share count 279,288,885 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full FMS picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for FMS and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.